Search Results for: 150

— Single Phase 3 Clinical Trial May be Sufficient for Approval for Prevention of Antibiotic-Mediated Clostridium difficile Infection (CDI) — — SYN-004 (ribaxamase) is in Development as Potentially the First Intervention Designed to Specifically Prevent Antibiotic Damage to the Microbiome — ROCKVILLE, Md., Nov. 21, 2018 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage […]

— Announced Agreement with Cedars-Sinai Medical Center to Co-fund a Phase 2b Investigator-Sponsored Clinical Study of SYN-010, for the Treatment of IBS-C — — Strengthened Balance Sheet in Support of Microbiome-Focused Clinical Development Programs — — Conference Call Today, November 8, 2018, at 4:30 p.m. (EST) — ROCKVILLE, Md., Nov. 8, 2018 /PRNewswire/ — Synthetic Biologics,

— Co-funded Research to be Led by Dr. Mark Pimentel’s Lab to Further Evaluate the Efficacy and Safety of SYN-010 in a 12-Week, Placebo-Controlled, Phase 2 Clinical Study — ROCKVILLE, Md., Sept. 6, 2018 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and

ROCKVILLE, Md., April 23, 2018 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, today announced that it has preliminary agreement from the U.S. Food & Drug Administration (FDA), on a proposed clinical trial synopsis for its planned

— Results from Phase 2b Proof-of-Concept Study Exploratory Endpoints Demonstrate Ribaxamase Protects and Preserves Gut Microbiome from Ceftriaxone-mediated Dysbiosis — — Two Ribaxamase and Two SYN-010 Presentations to be Included at Digestive Disease Week (DDW 2017) — — Conference Call Today, May 4, 2017, at 4:30 p.m. (EDT) — ROCKVILLE, Md., May 4, 2017 /PRNewswire/

— Company Highlights Clinical Successes of Late-stage Microbiome-focused Programs, Plans for Phase 3 Development — — Conference Call Today, March 2, 2017, at 4:30 p.m. (EST) — ROCKVILLE, Md., March 2, 2017 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health

— Enrollment in SYN-010 Pivotal Trial Will Be Open to All IBS-C Patients — ROCKVILLE, Md., Jan. 18, 2017 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, today confirmed plans to initiate a Phase 2b/3 adaptive pivotal

— Presentation Planned for 9:30am (PT), Jan. 9, 2017 at Biotech Showcase in San Francisco — ROCKVILLE, Md., Jan. 5, 2017 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, today announced positive topline data from its Phase 2b

– Held End of Phase 2 Meeting with FDA and Received Guidance for Advancement to First Pivotal Trial for SYN-010, for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) – – Company Provides Update on Enrollment for Phase 2b Proof-of-Concept Clinical Trial for SYN-004 (ribaxamase), for the Prevention of C. Difficile Infection (CDI) and

— Ribaxamase Designed for the Prevention of C. difficile Infection, Antibiotic-Associated Diarrhea & the Emergence of Antibiotic-Resistant Organisms — — Oral Presentation Planned for ANAEROBE 2016 — ROCKVILLE, Md., July 7, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on developing therapeutics to protect the gut microbiome while targeting pathogen-specific